Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood Purif. 2012;34(2):80-7. doi: 10.1159/000341644. Epub 2012 Oct 24.

Sensors and hybrid therapies: a new approach with automated citrate anticoagulation.

Author information

1
Division of Nephrology and Hypertension, Henry Ford Health System, Detroit, MI 48202, USA. bszamos1@hfhs.org

Abstract

BACKGROUND:

Hybrid therapies use intermittent hemodialysis (IHD) machines adapted to provide prolonged intermittent or continuous renal replacement therapy in the intensive care unit (ICU). Despite the low cost, hybrid therapy use is limited warranting a novel approach.

METHODS:

The literature was reviewed for limitations of hybrid protocols, use of regional citrate anticoagulation (RCA) on hybrid systems and sensors for IHD and hybrid therapy. The novel hybrid program in the authors' institution is presented as a plausible future direction for the modality.

RESULTS:

Hybrid therapies are limited by access flow and clotting alarms. Technology limitations render many IHD sensors inoperable at low dialysate flow. A synergy with RCA allows a novel, safe approach with low blood flows and high dialysate flows with alarm- and clotting-free operation and all commercial IHD sensors functional.

CONCLUSION:

The low cost, ease of use, safety and efficacy of hybrid therapy with near-automated RCA may lead to rapid expansion of this form of ICU renal support.

PMID:
23095406
DOI:
10.1159/000341644
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center